Login to Your Account


Immunocellular phase II GBM ‘shocker’ miss in OS: Fixable?

By Randy Osborne
Staff Writer

Friday, December 13, 2013
Oversized hopes for what the company designed as an exploratory Phase II trial led to Immunocellular Therapeutics Ltd.’s stock plunge, after the company disclosed mixed results with its dendritic cell-based vaccine in glioblastoma multiforme (GBM), said CEO Andrew Gengos.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription